Lenalidomide Desensitization in Systemic Light-Chain Amyloidosis With Multi-Organ Involvement

Limited therapeutic options are available to amyloid patients treated with many lines of therapy. Although combination therapy using lenalidomide and dexamethasone is an effective sequential regimen for systemic amyloidosis (AL), dexamethasone is often poorly tolerated in patients with cardiac invol...

Descripción completa

Detalles Bibliográficos
Autores principales: Seki, Jack T., Sakurai, Naoko, Kukreti, Vishal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554222/
https://www.ncbi.nlm.nih.gov/pubmed/26346623
http://dx.doi.org/10.14740/jocmr2303e

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554222/
https://www.ncbi.nlm.nih.gov/pubmed/26346623
http://dx.doi.org/10.14740/jocmr2303e

Ejemplares similares